Fig 1: MMP-19 and MMP-20 knockdown decreased the invasion abilities of ovarian cancer cells. The normalized percentages of invaded Cov362 (a) and Skov3 (b) after transfected with MMP-19 siRNA or MMP-20 siRNA or control were indicated as detected by Boyden Chamber Transwell method. (c) A representative cell invasion assay was shown. Cells were transfected with MMP-19 or MMP-20 siRNA or control and incubated for 24 h, seeded into Matrigel-coated transwell inserts, and incubated for another 48 h. Error bars, mean ± S.D. of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
Fig 2: MMP-19 and MMP-20 high expressions induced anti-cancer drug resistance. (a) MMP-19 and MMP-20 were assayed by Western Blotting in indicated ovarian carcinoma cell lines. The numbers listed below the blots indicate the optical density ratio of target protein to β-actin. (b–g) Direct comparison of cell death and viabilities of ovarian cancer cell lines with low (Ovcar8) and high (Cov362) MMP-20 expressions after the treatment of A-1210477 (b,d,f) and Vincristine (c,e,g). After the cell lines were treated with indicated drugs for 48 hours, the percentages of pre-G1 cells (b,c), Annexin V+ or PI+ cells (d,e), or the ratio of OD450 by WST-8 (f,g) were assayed. (h,i) Direct comparison of cell death and viabilities of ovarian cancer cell lines with low (Ovcar5) and high (Ho8910) MMP-19 expressions after the treatment of A-1210477 (h) and Vincristine (i). After the cell lines were treated with indicated drugs for 48 hours, the percentages of pre-G1 cells were measured. Error bars, mean ± S.D. of three independent experiments.
Fig 3: MMP-19 and MMP-20 knockdown increased anti-cancer drugs sensitivities. (a) After Skov3 and Cov362 cells were transfected with MMP-19 siRNA or control, the cells were harvested and the mRNA levels of MMP-19 were measured using quantitative PCR. (b) after the Skov3 and Cov362 cells were transfected with MMP-20 siRNA or control, the cells were collected and probed for MMP-20 by western blotting. (c–e) After Skov3 cells were transfected with MMP-19 or MMP-20 siRNAs or control followed by the treatment of A-1210477 (8 µM, c), Carboplatin (20 nM, d) or paclitaxel (40 nM, e), the percentage of pre-G1 cells were measured. (f–h) After Cov362 cells were transfected with MMP-19 or MMP-20 siRNAs or control followed by the treatment of A-1210477 (8 µM, f), Carboplatin (20 nM, g) or paclitaxel (40 nM, h), the percentage of pre-G1 cells were measured. Error bars, mean ± S.D. of three independent experiments. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.
Supplier Page from Abcam for Anti-MMP20 antibody